HCPCS code J9120: Dactinomycin, per 0.5 mg2026 Medicare rate & RVUs in Missouri
Reports dactinomycin, an intravenous antineoplastic drug, by 0.5 mg for oncology treatment when the drug is furnished and administered.
CMS doesn’t publish an office rate for J9120 in Missouri.
Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.
Your location
On this page 9 sections
What J9120 covers
Dactinomycin, also called actinomycin D, is an antineoplastic antibiotic given intravenously. Oncology clinicians use it in treatment regimens for cancers such as Wilms tumor, rhabdomyosarcoma, and gestational trophoblastic neoplasia. The drug may be furnished and administered in an office or hospital outpatient setting; the clinician or facility that supplies the drug reports the drug code. The administration service is identified separately when applicable.
CMS excludes J9120 from the physician fee schedule under status E. When Medicare covers the drug, payment is handled through another payment method; CMS classifies it as a Part B drug that generally uses the quarterly Average Sales Price drug pricing files when covered. Special Medicare coverage instructions apply. Each billing unit represents 0.5 mg of dactinomycin, so 1 mg corresponds to 2 units. Report units based on the amount administered and the code’s dose per unit.
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
Where J9120 pays more and less in Missouri
The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.
| Payment locality | Office | Facility |
|---|---|---|
| Metropolitan Kansas City, MO | Unavailable | Unavailable |
| Metropolitan St. Louis, MO | Unavailable | Unavailable |
| Rest of Missouri | Unavailable | Unavailable |
How the J9120 rate is calculated
Each of J9120’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.
How the rate is built · J9120
RVUs × geographic indexes × conversion factor
Work0.00
0.00 RVUs× 1.000 GPCI
Practice expense0.00
0.00 RVUs× 1.000 GPCI
Malpractice0.00
0.00 RVUs× 1.000 GPCI
Adjusted RVUs
0.0000
Conversion factor
$33.4009
Medicare rate
$0.00
Every GPCI starts at 1.000, the national rate. Enter a ZIP or drag a slider.
Payment rules and modifiers for J9120
J9120 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.
Place of service · J9120
Which rate does Medicare pay?
The POS code on the claim line (CMS-1500 box 24B).
POS 11 · non-facility rate · national
—
J9120 isn’t priced in this setting.
J9120 compared with similar codes
Compare codes · National
4 codes, side by side
How to choose
- J9130Dacarbazine injectionPer 100 mg
- J9130 identifies dacarbazine, a different antineoplastic drug, and its unit is based on 100 mg. Use J9120 for dactinomycin.
- J9150Daunorubicin injectionPer 10 mg
- J9150 identifies daunorubicin, not dactinomycin. Select the code for the drug actually furnished.
- J9100Cytarabine injectionPer 100 mg
- J9100 identifies cytarabine hydrochloride in 100 mg units. It is a different drug from dactinomycin, which J9120 reports in 0.5 mg units.
J9120 billing questions
How many units represent 1 mg of dactinomycin?
Each unit represents 0.5 mg, so 1 mg is 2 units. Calculate units from the amount administered.
How is J9120 different from the nearby chemotherapy drug codes?
J9120 identifies dactinomycin. Codes such as J9130 for dacarbazine and J9150 for daunorubicin identify different drugs, not alternate unit sizes for dactinomycin.
Does J9120 include chemotherapy administration?
J9120 identifies the drug. Report an applicable chemotherapy administration service separately when the administration is furnished and separately reportable.
How does Medicare treat J9120?
CMS assigns status E, excluding it from the physician fee schedule. When covered, it is treated as a Part B drug generally paid through the quarterly ASP drug pricing files, subject to special Medicare coverage instructions.
Where these rates come from
FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.
CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027
Fee sheets · Coming soon
Put J9120 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist